Trial
NCT04878432
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Myelodysplastic Syndrome (MDS)
Intervention
MBG453
Why stopped
Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-16